RxDoctor Payments Data

David Michelson

Neurology with Special Qualifications in Child Neurology · West Covina, CANPI 1043233737

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Genentech USA, Inc. at 42.9% of the total.

$6,997in general payments, 2019–2025

Across 77 payments — averaging $90.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$3K
  • ITF Therapeutics LLC$2K
  • Catalyst Pharmaceuticals, Inc.$624
  • Acadia Pharmaceuticals Inc$482
  • AbbVie$218
  • Biogen$198
  • plus $713 from 10 others
$171,171in research payments, 2019–2025

Across 74 payments — averaging $2313.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$39K
  • Teva Pharmaceuticals USA, Inc.$38K
  • PTC Therapeutics, Inc.$33K
  • Genentech, Inc.$23K
  • Mallinckrodt Enterprises LLC$18K
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$10K
  • plus $11K from 3 others

What the payments were for

  • Consulting fees$3,00043%
  • Speaking & faculty fees$2,58937%
  • Food & beverage$1,17517%
  • Education$2343%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,997 in reported general payments places this provider in the 75th percentile of 216 neurology with special qualifications in child neurology providers in California.

See all neurology with special qualifications in child neurology providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam24$649,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$3,000$649,45324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 216 neurology with special qualifications in child neurology providers in California.

Other neurology with special qualifications in child neurology in West Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →